New hope for rare blood cancer: phase 3 trial of XNW5004 launches
NCT ID NCT06776952
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 21 times
Summary
This study tests a new drug, XNW5004, against an existing treatment (Chidamide) for people with a rare blood cancer called peripheral T-cell lymphoma that has come back or not responded to prior therapy. About 120 adults aged 18-70 will participate. The main goal is to see if XNW5004 can delay cancer growth better than the current standard.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.